Concepedia

Ryohei Kozaki

RK

Statistics

Publications

11

Citations

335

H-Index

10

Active since

2000

Affiliations

Ono Pharmaceutical (Japan)(Current)

Kyoto Prefectural University of Medicine

Kanazawa University

Ryohei Kozaki is an author at Ono Pharmaceutical (Japan) specializing in pharmacology, medicine, and oncology.

Publications per year

2000–2024

11

Publications

11

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer

Naoko Okura, Naoya Nishioka, Tadaaki Yamada et al. · Clinical Cancer Research · 2020 · 113 citations

Medicine, Oncology, Pharmacology +17

Efficacy and immunomodulatory actions of ONO-4641, a novel selective agonist for sphingosine 1-phosphate receptors 1 and 5, in preclinical models of multiple sclerosis

Takaki Komiya, Kazutoyo Sato, Hiroki Shioya et al. · Clinical & Experimental Immunology · 2012 · 49 citations · Full text

Life Sciences, Immunology, Pharmacology +14

Responses to the Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines

Ryohei Kozaki, Meike Vogler, Harriet S. Walter et al. · Cancers · 2018 · 32 citations · Full text

Medicine, Hematology, Pharmacology +17

AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill <i>FLT3</i>-ITD acute myeloid leukemia

Sean M. Post, Huaxian Ma, Prerna Malaney et al. · Haematologica · 2021 · 32 citations · Full text

Medicine, Oncology, Pharmacology +16

Anti-tumor efficacy study of the Bruton’s tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior<i>in vivo</i>efficacy compared to ONO/GS-4059 in combination with rituximab

Tomoko Yasuhiro, Wako Sawada, Christian Klein et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2016 · 21 citations

Medicine, Oncology, Pharmacology +17

1–5 of 11